Literature DB >> 7049658

Fixed combination drug therapy.

G M Shenfield.   

Abstract

Almost half of all marketed drugs are fixed combination preparations, yet the World Health Organization included only 7 in its list of 240 "essential' drugs. There has been little scientific study of these preparations but much emotion and rhetoric has been expended both for and against them. Potential advantages of fixed combination preparations include: increased compliance, synergy and increased efficacy, and reduced side effects and cost. Potential disadvantages include: inflexible fixed dose ratio, incompatible pharmacokinetics, increased toxicity, and physician and pharmacist ignorance of content. There are a few combinations of undisputed value such as oral contraceptives, levodopa with decarboxylase inhibitors, and pyrimethamine with sulphadoxine. In other cases fixed-dose combinations may have value in strictly specified circumstances, but are probably overprescribed. There is also widespread, unjustified use of combinations in over-the-counter preparations which may have unrecognised adverse effects. Combinations should only be used if each component is necessary for the desired effect and if the advantages outweigh the added risks of using 2 or more drugs. Before prescribing combination drugs, clinicians should always ask themselves a series of questions of which the most important is whether the patient needs each drug in a particular combination, or if 1 component alone would be adequate. In general, government regulatory bodies in "developed' countries are attempting to curb the use of combination drugs, but a more profitable approach might be to better educate doctors on both the advantages and disadvantages of fixed combination preparations leading to improved prescribing habits.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7049658     DOI: 10.2165/00003495-198223060-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  67 in total

1.  Letter: A survey of hospital pharmacists' knowledge of the content of drug combinations.

Authors:  J Gagné; P Biron; R Moisan
Journal:  Ann Intern Med       Date:  1975-05       Impact factor: 25.391

2.  The antibiotic treatment of typhoid fever.

Authors:  A M Geddes
Journal:  J Antimicrob Chemother       Date:  1977-09       Impact factor: 5.790

3.  Dosage of potassium chloride elixir to correct thiazide-induced hypokalemia.

Authors:  A B Schwartz; C D Swartz
Journal:  JAMA       Date:  1974-11-04       Impact factor: 56.272

4.  A hopefully biased pilot survey of physicians' knowledge of the content of drug combinations.

Authors:  P Biron
Journal:  Can Med Assoc J       Date:  1973-07-07       Impact factor: 8.262

5.  Co-trimoxazole - too toxic for minor infections?

Authors: 
Journal:  Drug Ther Bull       Date:  1979-08-17

6.  The effects of potassium supplements, spironolactone of amiloride on the potassium status of patients with heart failure.

Authors:  C Davidson; L Burkinshaw; D B Morgan
Journal:  Postgrad Med J       Date:  1978-06       Impact factor: 2.401

Review 7.  Clinical use of topical cortisteroids.

Authors:  I B Sneddon
Journal:  Drugs       Date:  1976       Impact factor: 9.546

Review 8.  Trimethoprim: a review of its antibacterial activity, pharmacokinetics and therapeutic use in urinary tract infections.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-06       Impact factor: 9.546

9.  Hypertension after ingestion of Trimolets.

Authors:  D B Frewin; P P Leonello; M E Frewin
Journal:  Med J Aust       Date:  1978-11-04       Impact factor: 7.738

10.  Trimethoprim resistance in Finland after five years' use of plain trimethoprim.

Authors:  P Huovinen; P Toivanen
Journal:  Br Med J       Date:  1980-01-12
View more
  8 in total

1.  Novel Curcumin-Resveratrol Solid Nanoparticles Synergistically Inhibit Proliferation of Melanoma Cells.

Authors:  Gayathri Heenatigala Palliyage; Noor Hussein; Michael Mimlitz; Catherine Weeder; Marya Hassan A Alnasser; Somnath Singh; Andrew Ekpenyong; Amit K Tiwari; Harsh Chauhan
Journal:  Pharm Res       Date:  2021-05-12       Impact factor: 4.200

2.  Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology.

Authors:  E J Ariëns
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 3.  Combination bronchodilator therapy.

Authors:  G M Shenfield
Journal:  Drugs       Date:  1982-11       Impact factor: 9.546

4.  Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians.

Authors:  Jieon Lee; Su-Jin Rhee; SeungHwan Lee; Kyung-Sang Yu
Journal:  Drug Des Devel Ther       Date:  2018-04-06       Impact factor: 4.162

5.  Potential combination topical therapy of anal fissure: development, evaluation, and clinical study†.

Authors:  Amgad E Salem; Elham A Mohamed; Hosam M Elghadban; Galal M Abdelghani
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

Review 6.  Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review.

Authors:  Ana Baumgartner; Katarina Drame; Stijn Geutjens; Marja Airaksinen
Journal:  Pharmaceutics       Date:  2020-02-22       Impact factor: 6.321

Review 7.  Multidrug resistance crisis during COVID-19 pandemic: Role of anti-microbial peptides as next-generation therapeutics.

Authors:  Sheetal Sharma; Panchali Barman; Shubhi Joshi; Simran Preet; Avneet Saini
Journal:  Colloids Surf B Biointerfaces       Date:  2021-12-20       Impact factor: 5.268

8.  Bromodomain and Extra-Terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection In Vitro and Ex Vivo by Increasing CDK9 Phosphorylation and Recruitment.

Authors:  Xu-Sheng Huang; Ren-Rong Tian; Meng-Di Ma; Rong-Hua Luo; Liu-Meng Yang; Guang-Hui Peng; Mi Zhang; Xing-Qi Dong; Yong-Tang Zheng
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.